As a member-based organisation, anticipating and supporting the needs of our members is critical. To give context to this I’d like to highlight two examples of this in action: The development of a statistical-based methodology for the prediction of Mutagenicity; Sarah Nexus. In the mid to late 2000s individual regulators had issued guidelines allowing the […]
Anticipating and supporting the needs of our members Read More »
An award honouring the scientific contributions and memory of Dr. Richard Williams, has been set up to support early career investigators within industry. Supported by the Industrial Genotoxicology Group (IGG), The Richard Williams Memorial Award will sponsor one individual a year to attend and present at the United Kingdom Environmental Mutagen Society (UKEMS) meeting. The
The Richard Williams Memorial Award Read More »
The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Updated regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at
Lhasa Limited supports the global challenge of nitrosamine impurity assessment Read More »
In May, Lhasa hosted a webinar titled; The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment. In case you missed this event, Senior Scientist, Alun Myden has provided an overview of the presentation and the work which Lhasa is doing in this area. An Introduction to AOPs AOPs are a formalised approach to documenting mechanisms